



HAL
open science

Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria

Arienne Mirmiran, Antoine Poli, Cecile Ged, Caroline Schmitt, Thibaud Lefebvre, Hana Manceau, Raed Daher, Boualem Moulouel, Katell Peoc'H, Sylvie Simonin, et al.

► To cite this version:

Arienne Mirmiran, Antoine Poli, Cecile Ged, Caroline Schmitt, Thibaud Lefebvre, et al.. Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. *Haematologica*, In press, pp.haematol.2019.228270. 10.3324/haematol.2019.228270 . inserm-02441267

HAL Id: inserm-02441267

<https://inserm.hal.science/inserm-02441267>

Submitted on 15 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria

Arienne Mirmiran,^{1*} Antoine Poli,^{1-3*} Cecile Ged,^{4,5} Caroline Schmitt,¹⁻³ Thibaud Lefebvre,¹⁻³ Hana Manceau,^{1,2,6} Raêd Daher,¹⁻³ Boualem Moulouel,³ Katell Peoc'h,^{1,2,6} Sylvie Simonin,^{1,3} Jean-Marc Blouin,^{4,5} Jean-Charles Deybach,¹⁻³ Gaël Nicolas,¹ Hervé Puy,¹⁻³ Emmanuel Richard,^{4,5,§} and Laurent Gouya^{1-3,5§}

¹Institut National de la Santé et de la Recherche Médicale U1149, Centre de Recherches sur l'Inflammation, Paris, France

²Université de Paris, Paris, France

³Assistance Publique-Hôpitaux de Paris, Centre Français des Porphyries, Hôpital Louis Mourier, Colombes, France

⁴Univ. Bordeaux, INSERM, BMGIC, U1035, CHU Bordeaux, Bordeaux, France.

⁵Laboratory of excellence Gr-Ex, Paris, France.

⁶Assistance Publique-Hôpitaux de Paris, HUPNVS, Laboratoire de Biochimie, Hôpital Beaujon, Clichy, France

*Both authors contributed equally to the work.

§Both authors share coseniorship.

Running head: Phlebotomy: a safe and efficient CEP treatment

Corresponding authors:

Laurent Gouya

Louis Mourier Hospital, Centre Français des Porphyries, 148 rue des Renouillers, 92700 Colombes, France. E-mail: laurent.gouya@inserm.fr

laurent.gouya@inserm.fr

Phone: +33 1 47 60 63 34, fax: +33 1 47 60 67 03

Emmanuel Richard

Université de Bordeaux INSERM U1035 "biothérapie des maladies génétiques, inflammation et cancers", 146 rue Léo Saignat FR-33000 Bordeaux, France

emmanuel.richard@u-bordeaux.fr

Phone: +335 57 57 13 73

Number of figures and tables: 3

Word count: 1498

Number of references: 15

Supplemental files: 1

Acknowledgments

The authors thank the affected individuals and their families who kindly contributed to this study and Dr N. Talbi who helped greatly with patient monitoring.

This study was supported by a grant from Laboratory of Excellence GR-Ex, reference ANR-11-LABX-0051. A.M. was supported by a Labex GR-Ex scholarship. The Labex GR-Ex is funded by the program “Investissements d’avenir” of the French National Research Agency, reference ANR-11-IDEX-0005-02.

Authorship

Contributions: A.P., A.M. and L.G. wrote the manuscript. H.P., J.C.D., C.G., E.R. and L.G. designed the protocol and experiments. L.G. followed patients’ clinical courses. A.P., A.M., C.S., T.L., S.S. and K.P. performed the biochemistry studies and cell culture. C.G., JMB and E.R. performed the molecular studies. All authors analyzed the data and edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Congenital erythropoietic porphyria (CEP, MIM 263700) is a rare autosomal recessive disease caused by impaired activity of uroporphyrinogen III synthase, the fourth enzyme of the heme biosynthetic pathway.¹ Accumulation of porphyrin in red blood cells, mainly uroporphyrinogen I (URO I) and coproporphyrinogen I (COPRO I), leads to ineffective erythropoiesis and chronic hemolysis. Porphyrin deposition in the skin is responsible for severe photosensitivity resulting in bullous lesions and progressive photomutilation. Treatment options are scarce, relying mainly on supportive measures and, for severe cases, on bone marrow transplantation (BMT). Increased activation of the heme biosynthetic pathway by gain-of-function mutations in *ALAS2*, the first and rate-limiting enzyme, results in a more severe phenotype.² Iron deficiency promotes the binding of iron regulatory protein to the 5'UTR iron-responsive elements of *ALAS2* mRNA and therefore decreases its translation.³ Egan et al. observed a 32-year-old woman with CEP who exhibited spontaneous improvement in photosensitivity and hemolysis after chronic gastrointestinal bleeding that resulted in iron deficiency.⁴ They treated her with an iron chelator, resulting in hemolysis correction, decreased porphyrin levels and improvement quality of life with reduced photosensitivity. We recently identified 3 CEP siblings with phenotypes ranging from moderate to asymptomatic modulated by iron availability, highlighting the importance of iron metabolism in the disease. Based on these data, we prospectively treated a CEP patient with phlebotomies to investigate the feasibility, safety and efficacy of this treatment. We observed discontinuation of hemolysis and a marked decrease in plasma and urine porphyrins. The patient reported a major improvement in photosensitivity. Finally, erythroid cultures were performed, demonstrating the role of iron in the rate of porphyrin production.

The study was conducted in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects.

A 49-year-old Caucasian female was treated for CEP by iterative phlebotomies for almost 2 years. She was diagnosed with CEP at age 25 after experiencing symptoms since the age of 4, including photosensitivity with skin fragility, blistering and scarring, mouth lesions with erythrodontia, microstomia and gum recession, sclerodermiform

retraction of the skin on face and hands and loss of a distal phalange. She showed moderate chronic hemolysis. Genetic testing revealed a homozygous *UROS* variant, p.Gly58Arg, resulting in markedly decreased UROS activity in RBCs (1.7 U/mg Hb/h, N>6). The patient was treated mainly by supportive measures, such as sun avoidance. At diagnosis, urine porphyrin levels were 2642 nmol/mmol of creatinine (URO 1602 nmol/mmol and COPRO 1040 nmol/mmol). Treatment started with the removal of 100 mL of blood twice a month during a month. Then, the volume of blood was increased by 50 mL each month or each month and a half until reaching 300 mL to avoid a strong induction of erythropoiesis. The iron store was efficiently depleted 8 months after the first phlebotomy, and the ferritin level decreased to 10.4 µg/L (Figure 1A). Concomitantly, we observed a significant decrease in urine and plasma porphyrin levels at 389 nmol/mmol and 50 nmol/L, corresponding to a 79% and an 85% decreases compared to those at baseline. A progressive normalization of haptoglobin levels occurred that was associated with a decrease in reticulocyte count, showing hemolysis discontinuation (Figure 1C). Photosensitivity markedly improved, and the urine became clearer. Phlebotomies were discontinued for 3 months, resulting in an increase in urine and plasma porphyrins (urine porphyrins 1956 nmol/mmol, plasma porphyrins 219 nmol/L) associated with worsening of photosensitivity. Phlebotomies were reintroduced at month 11, on a monthly basis, progressively increasing the blood volume over 7 months until reaching 300 mL. Phlebotomies were then continued at 200 mL monthly. At month 18, low levels of urine and plasma porphyrins were obtained again (460 nmol/mmol and 31 nmol/L, respectively). Finally, at month 23, urine and plasma porphyrin levels were reduced to 271 nmol/mmol and 26 nmol/L (minus 83% and 91% compared to baseline), close to that observed after BMT⁵. During the course of treatment, total erythrocyte porphyrins levels were moderately reduced (8.7 µmol/L at baseline, 7.3 µmol/L at month 23, 16% decrease, Figure 1B). Erythrocyte porphyrins chromatography prior to phlebotomies revealed that it was composed of 62,4% PPIX (5,43 µmol/L), 19,9% URO (1,73 µmol/L) and 15% COPRO (1,30 µmol/L). At month 23 of treatment, erythrocyte porphyrins chromatography showed a large decrease in URO (1.1%, 0.08 µmol/L, 95% decrease compared to baseline) and COPRO (8.6%, 0.63 µmol/L, 51% decrease) and an increase amount of PPIX (89.3%, 6.52 µmol/L, 20% increase, 76% of Zinc PPIX) due to iron deficiency anemia. Hemoglobin levels remained greater than 10 g/dL. Clinical tolerance was good with moderate asthenia. Her urine became

clear. No adverse effects were detected. The biological and clinical improvement allowed the patient to have unrestricted solar exposure during summer without showing any signs of blistering.

The impact of iron metabolism on CEP clinical expression is reinforced by the observation of a consanguineous Pakistani family with three of four children diagnosed with CEP (Figure 2A). Their *UROS* genotype was associated with mild CEP presentation in an Indian family.⁶ The proband (subject II1), a 9-year-old girl, exhibited photosensitivity, skin fragility and blistering, hirsutism and mild, compensated hemolysis without iron deficiency. She had markedly elevated urine and plasma porphyrin levels (Figure 2B). Her 5-year-old affected brother (subject II3) never experienced any CEP symptoms with unrestricted sun exposure. His plasma porphyrin levels were in the normal range. Urine porphyrin levels, mostly consisting of isomer I, were almost normal and 56-fold lower than his sister. He had mild aregenerative microcytic anemia without hemolysis due to a profound iron deficiency. G6PD and pyruvate kinase activity and hemoglobin electrophoresis were normal. There was no report of bleeding. Patient II1 and II3 total erythrocyte porphyrin levels were similar but chromatographic profiles showed mainly URO and COPRO in subject II1, and 92% PPIX (ZnPPIX 73%) in subject II3, as observed in the patient treated with phlebotomies (Figure 2B). Patient II4, a 2-month-old new-born, was free of skin symptoms but had normocytic anemia with moderate hemolysis. His ferritin levels were quite high at 165 µg/L. He had increased plasma and urine porphyrin levels.

To investigate the role of iron in the rate of porphyrin production we differentiated erythroid cells, derived from patient peripheral CD34+ cells, by adapting the protocol of Mirmiran et al⁷ by varying holo-transferrin concentration from 20 to 2000 µg/mL (Table S1). Blood was obtained from the CEP patient's phlebotomy. Erythroid differentiation was monitored by flow cytometry using anti-CD36 and anti-CD235. Differentiation was similar in every condition of holo-transferrin concentration (Figures S1 and S2). Total erythroid cell porphyrin measurements showed an increase in porphyrin levels, with approximately twice the level of porphyrin in the 700 µg/mL holo-transferrin condition, compared to the 200 µg/mL condition (Figure 3A). At higher concentrations (1000, 1500 and 2000 µg/mL), there is a slight decrease in porphyrin levels probably due to iron toxicity. Chromatography revealed that this

augmentation was due to an increase in URO and COPRO production, while PPIX levels remained stable (Figure 3B). These data showed that CEP erythroid cells produce less URO and COPRO and that the proportion of PPIX increases when iron is less available. Thus, those *in vitro* findings confirm the *in vivo* data where URO and COPRO levels decreased when the iron store was depleted.

Treatment options for CEP patients are scarce. Photomutilations are prevented by sun avoidance. Hemolytic anemia is managed by hypertransfusions to decrease hematopoiesis and thereby porphyrin production.⁸ This treatment has limited success and is responsible for severe secondary hemochromatosis.⁵ Patients often require BMT.⁹ An iron chelator (deferasirox) was successfully used to treat a patient with CEP who showed improved photosensitivity and erythropoiesis.⁴ The use of an iron chelator is a suitable treatment under iron overload, but its benefit and toxicity have not been evaluated in normal and iron-deficient states. Chronic Deferasirox use is associated with toxicities such as gastrointestinal hemorrhage and renal and liver failure.¹⁰ Conversely, phlebotomies have been safely used as a long-term treatment in adults and children with hemoglobin SC disease to reduce blood viscosity.^{11,12} Nevertheless, an iron chelator could be used initially to deplete iron stores. Phlebotomy could then be used to maintain low ferritin level. This sequential strategy avoids initial erythropoiesis induction and iron chelators long-term toxicity. After iron store restriction, our patient's urine porphyrin levels reached a level close to that observed in CEP patients post-BMT.¹³ Iron deficiency anemia was partially compensated by hemolysis correction and hemoglobin count remained greater than 10 g/dL. Finally, the observation of siblings with contrasting phenotypes modulated by iron availability highlights the importance of iron regulation in CEP. This study strengthens the hypothesis that the heme biosynthesis pathway can be slowed by inducing a mild iron deficiency anemia. This is likely achieved by decreasing ALAS2 mRNA translation.⁴ More ALAS2 expression studies need to be performed to conclusively confirm this mechanism.¹⁴ We can thus propose phlebotomies as a simple, universally available, well-tolerated and inexpensive strategy for treating CEP. Phlebotomies should be used in patients with hemolytic anemia without need of chronic transfusion or when BMT is not available, the latter remaining the first-line treatment in transfusion-dependent patients.

References

1. Erwin AL, Desnick RJ. Congenital erythropoietic porphyria: Recent advances. *Mol Genet Metab*; (October 2018): [Epub ahead of print].
2. To-Figueras J, Ducamp S, Clayton J, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. *Blood* 2011;118(6):1443–1451.
3. Bhasker CR, Burgiel G, Neupert B, Emery-Goodman A, Kühn LC, May BK. The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control. *J Biol Chem* 1993;268(17):12699–705.
4. Egan DN, Yang Z, Phillips J, Abkowitz JL. Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria. *Blood* 2015;126(2):257–261.
5. Katugampola RP, Anstey A V., Finlay AY, et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. *Br J Dermatol* 2012;167(4):888–900.
6. Xu W, Warner CA, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. *J Clin Invest* 1995;95(2):905–912.
7. Mirmiran A, Schmitt C, Lefebvre T, et al. Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyrin. *Am J Hum Genet* 2019;104(2):341–347.
8. Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete Suppression of the Symptoms of Congenital Erythropoietic Porphyria by Long-Term Treatment with High-Level Transfusions. *N Engl J Med* 1986;314(16):1029–1031.
9. Peinado CM, Díaz De Heredia C, To-Figueras J, et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. *Pediatr Dermatol* 2013;30(4):484–489.
10. Kontoghiorghes GJ, Kontoghiorghes CN. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. *Drug Des Devel Ther* 2016;10465.
11. Naessens V, Ward R, Kuo KHM. A proposed treatment algorithm for adults with Haemoglobin SC disease. *Br J Haematol* 2018;182(4):607–609.
12. Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell disease complications: A clinical study of 179 cases. *Haematologica* 2012;97(8):1136–1141.
13. Katugampola RP, Badminton MN, Finlay AY, et al. Congenital erythropoietic porphyria: A single-observer clinical study of 29 cases. *Br J Dermatol* 2012;167(4):901–913.

14. Barman-Aksözen J, Minder EI, Schubiger C, Biolcati G, Schneider-Yin X. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability. *Blood Cells, Mol Dis* 2015;54(1):71–77.
15. Deacon AC, Elder GH. Front line tests for the investigation of suspected porphyria. *J Clin Pathol* 2001;54(7):500–507.

Figure 1. Patient clinical and biological parameters throughout treatment.

A: urine porphyrins (gray), plasma porphyrins (blue) and ferritin (dark red). B: erythrocyte porphyrins (brown), protoporphyrins (light green), coproporphyrins (purple) and uroporphyrins (orange). C: hemoglobin (dark blue), reticulocytes (red) and haptoglobin (dark green). At baseline, urine porphyrins/creatinine ranged from 1845 to 2565 nmol/mmol (reference <30), plasma porphyrins ranged from 227 to 289 nmol/L (reference <20), reticulocyte counts ranged from 115 to 128 x 10⁹/L (reference range, 20-80), the haptoglobin level was 0.16 g/L (reference range, 0.56 – 2) and ferritin ranged from 120 to 150 µg/L (reference range, 18 - 160). Over the entire treatment course, ferritin levels were not greater than 17 µg/L.

Figure 2. CEP family pedigree and biological parameters at diagnosis.

A: The family pedigree showing 3 of 4 siblings diagnosed with CEP (M: *UROS* c.660+4delA, +: wild type allele). Genetic testing confirmed the diagnosis: patients II1, II3 and II4 are homozygous for the *UROS* mutation c.660+4delA, previously reported.⁶ B: Siblings laboratory values at diagnosis. ND: not determined. NA: not applicable.

Figure 3. *In vitro* erythroid cell porphyrin analysis.

Cells were harvested at D18 for total erythroid cell porphyrin assessment and porphyrin separation by HPLC with fluorescence detection. Erythrocyte, plasma and urine porphyrins were measured as previously described.¹⁵ A: Porphyrin levels in erythroid cells derived from peripheral CD34+, normalized by protein content after culture in ascending concentrations of holo-transferrin. Porphyrins were not detectable in the 20 µg/mL condition, presumably given the technique's insufficient sensibility. B: quantification and separation of the different types of porphyrins in erythroid cells by chromatography. C: the ratio of PPIX to COPRO level plus URO level ranged from approximately 0.3 in iron-depleted conditions to 0.15 in iron-replete conditions.